Cofactor Genomics, announced that Medicare contractor Palmetto GBA has approved national coverage for their test, OncoPrism. This test is designed to help doctors predict how well cancer patients will respond to immunotherapy.
OncoPrism focuses on patients with recurrent and metastatic head and neck squamous cell carcinoma (RM-HNSCC), using RNA data to analyze a patient’s tumor immune profile. The goal is to provide doctors with more information about whether patients are likely to respond to immune checkpoint inhibitor treatments, either on their own or with chemotherapy.
Jarret Glasscock, CEO of Cofactor Genomics, said, “This is a win for everyone working to improve precision medicine in cancer care. But most importantly, it’s a win for patients, because having more accurate predictions means doctors can make better treatment decisions and potentially improve outcomes.”
RM-HNSCC is one of 11 types of cancer currently being studied in a national clinical trial (PREDAPT, NCT04510129), which is evaluating how well OncoPrism can predict a patient’s response to ICI treatments.
Cofactor Genomics specializes in using RNA to develop diagnostic tools that help address some of the challenges in healthcare. Instead of relying on traditional gene mutation panels, the company uses machine learning and RNA models, called Health Expression Models, to analyze biological data and better understand disease and treatment responses.